Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5 Thoracic 3 Gynecologic 3 Gastrointestinal 3 Plasma cell 2 Other solid neoplasm 2 Other hematologic neoplasm 2 Lymphoid 2 CNS 2 Tumor-Agnostic 1 Myeloid 1 Head & Neck 1 Genitourinary 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 69 Nivolumab 57 Ipilimumab 36 Specimen Handling 32 Magnetic Resonance Spectroscopy 25 Cyclophosphamide 22 Biopsy 18 cemiplimab 14 fludarabine 13 relatlimab 11 binimetinib 11 Opdualag 11 CTLA-4 Antigen 11 trametinib 10 fludarabine phosphate 10 Radiosurgery 10 avelumab 9 lifileucel 8 dabrafenib 8 Radiotherapy 8 atezolizumab 7 aldesleukin 7 Paclitaxel 7 Blood Specimen Collection 7 encorafenib 6 X-Rays 6 Standard of Care 6 Interleukin-2 6 Immunoglobulin G 6 HhAntag691 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Palliative Care × Dermatologic × 90 days × Clear all

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡